Citigroup Global Markets Limited Form 38.5(a) (EPTRI) -Sanofi (4567I)
2022年12月2日 - 8:15PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDM0A2V
RNS Number : 4567I
Citigroup Global Markets Limited
02 December 2022
FORM 38.5(a) (EPT/RI)
IRISH TAKEOVER PANEL
DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH
TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022
BY A CONNECTED EXEMPT PRINCIPAL TRADER WITH
RECOGNISED INTERMEDIARY STATUS AND DEALING IN
A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
(a) Name of exempt principal trader: Citigroup Global Markets Limited
(b) Name of offeror/offeree in relation to whose relevant securities this Sanofi
form relates:
Use a separate form for each offeror/offeree
---------------------------------
(c) Name of the party to the offer with which exempt principal trader is Amgen Inc
connected: (Note
1)
---------------------------------
(d) Date dealing undertaken: 01 December 2022
---------------------------------
(e) In addition to the company in 1(b) above, is the exempt principal trader Horizon Therapeutics plc and
also making Amgen Inc
disclosures in respect of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
---------------------------------
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(b), copy
table 2(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
Ap35
(a) Purchases and sales
Class Purchases/ Total Highest Lowest
of sales number price price
relevant of per per
security securities unit paid/ unit paid/
(Note received received
3) (EUR) (EUR)
ordinary
shares Purchase 669,352 91.6400 86.2250
------------ ------------ ------------ ------------
ordinary
shares Sale 461,073 91.6400 86.2250
------------ ------------ ------------ ------------
(b) Cash-settled derivative transactions
Class Product Nature of Number Price
of description dealing of per
relevant e.g. CFD e.g. opening/closing reference unit
security a long/short securities (Note
position, (Note 5)
increasing/reducing 4)
a
long/short
position
ordinary Increasing
shares TRS Short Position 2 87.4400
-------------- ----------------------- ------------ --------
ordinary Increasing
shares TRS Short Position 61 87.1374
-------------- ----------------------- ------------ --------
ordinary Increasing
shares TRS Short Position 1 87.1000
-------------- ----------------------- ------------ --------
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number Exercise Type Expiry Option
relevant description purchasing, of price per e.g. date money
security e.g. call option selling, securities unit American, paid/
varying etc. to which European received
option etc. per unit
relates
(Note 4)
(ii) Exercise
Class of Product Exercising/ Number of Exercise price
relevant description exercised securities per unit
security e.g. call option against (Note 5)
(d) Other dealings (including transactions in respect of new securities)
Class of relevant security Nature of Details Price per unit
dealing (if applicable)
e.g. subscription, (Note 5)
conversion,
exercise
Ap36
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the exempt principal trader making the disclosure and any party
to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing
and any other person relating to the voting rights of any relevant securities under any option
referred to on this form or relating to the voting rights or future acquisition or disposal
of any relevant securities to which any derivative referred to on this form is referenced.
If none, this should be stated.
Date of disclosure: 02 December 2022
Contact name: Craig Watson
-----------------
Telephone number: 028 90 409605
-----------------
Public disclosures under Rule 38 of the Rules must be made to a
Regulatory Information Service.
Ap37
NOTES ON FORM 38.5(a)
1. See the definition of "connected principal trader" in Rule
2.2 of Part A of the Rules.
2. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.
3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.
4. See Rule 2.5(d) of Part A of the Rules.
5. If the economic exposure to changes in the price of
securities is limited, for example, by virtue of a stop loss
arrangement relating to a spread bet, full details must be
given.
6. If details included in a disclosure under Rule 38 are
incorrect, they should be corrected as soon as practicable in a
subsequent disclosure. Such disclosure should state clearly that it
corrects details disclosed previously, identify the disclosure or
disclosures being corrected, and provide sufficient detail for the
reader to understand the nature of the corrections. In the case of
any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rules 8 and 38
of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish
Takeover Panel Act, 1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEEAFAAEFFAFFA
(END) Dow Jones Newswires
December 02, 2022 06:15 ET (11:15 GMT)
Sanofi (LSE:0A2V)
過去 株価チャート
から 11 2024 まで 12 2024
Sanofi (LSE:0A2V)
過去 株価チャート
から 12 2023 まで 12 2024
